Portfolio company Epicrispr Biotechnologies closed a $90M Series C co-led by Octagon Capital and Janus Henderson; its EPI-321 epigenetic therapy for FSHD showed positive Phase 1/2 results.
Epicrispr Biotechnologies is developing therapies to dynamically control gene expression and treat complex diseases using epigenetic editing
Epicrispr Biotechnologies is developing therapies to dynamically control gene expression and treat complex diseases using epigenetic editing.